<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831207</url>
  </required_header>
  <id_info>
    <org_study_id>upeclin/HC/FMB-Unesp-19</org_study_id>
    <nct_id>NCT00831207</nct_id>
  </id_info>
  <brief_title>Beta-2 Microglobulin and Serum Cytokines x HAART</brief_title>
  <official_title>Beta-2 Microglobulin and Serum Cytokines as Indicators of Antiretroviral Therapy Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UPECLIN HC FM Botucatu Unesp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UPECLIN HC FM Botucatu Unesp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-sectional study to assess the behavior of Beta-2 microglobulin and serum cytokines
      TNF-α, IFN-γ, IL-2, IL-4 and IL-10 as indicators of highly active antiretroviral therapy
      (HAART) failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To assess the behavior of Beta-2 microglobulin and serum cytokines TNF-α, IFN-γ,
      IL-2, IL-4 and IL-10 as indicators of highly active antiretroviral therapy (HAART) failure
      Design: Cross-sectional study. Methods: Eighty-nine HIV-1+ patients and 20 normal individuals
      were divided into 4 groups: G1- 15 HIV-1+ individuals, previously untreated or without HAART
      for at least six months and CD4+ &lt; 350 cells/mm3; G2- 31 HIV-1+ individuals undergoing HAART
      without virological therapeutic failure (TF), G3- 43 HIV-1+ individuals undergoing HAART with
      TF, and GC- 20 normal individuals who served as controls for serum cytokines. Demographic,
      clinical and HAART data were reviewed, and Beta-2 microglobulin, serum cytokines (TNF-α,
      IFN-γ, IL-2, IL-4 and IL-10), HIV-1 genotyping, plasma viral load and CD4+ and CD8+
      lymphocytes tests were performed.

      Key words: Beta-2 microglobulin, serum cytokines, HIV-1, resistance, HAART, therapeutic
      failure, genotyping.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the behavior of Beta-2 microglobulin as indicator of highly active antiretroviral therapy (HAART) failure.</measure>
    <time_frame>At subject enrollment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the behavior of serum cytokines TNF-α, IFN-γ, IL-2, IL-4 and IL-10 as indicators of highly active antiretroviral therapy (HAART) failure.</measure>
    <time_frame>At subject enrollment.</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">109</enrollment>
  <condition>HIV Patients</condition>
  <arm_group>
    <arm_group_label>G1</arm_group_label>
    <description>15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ &lt; 350 cells/mm3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G2</arm_group_label>
    <description>31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G3</arm_group_label>
    <description>43 HIV-1+ individuals undergoing HAART with TF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G4</arm_group_label>
    <description>20 normal individuals who served as controls for serum cytokines.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        89 HIV-1-infected individuals assisted by the Tropical Diseases Sector of the Botucatu
        School of Medicine - UNESP and 20 normal blood donors at the Botucatu Blood Bank.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1-infected individuals

          -  Over 18 years old

          -  Sign the &quot;written consent form&quot; (WCF)

        Exclusion Criteria:

          -  Do not presenting other immunosuppression causes, such as neoplasias, transplantations

          -  Do not presenting treatment by immunosuppressive substances

          -  Do not presenting auto-immune diseases

          -  Not be using any type of immunostimulating substances

          -  Not at any time of gestation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo MB Almeida, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Doencas Tropicais e Diagnostico por Imagem - Faculdade de Medicina de Botucatu - UNESP.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculdade de Medicina de Botucatu - UNESP</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2008</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>January 27, 2009</last_update_submitted>
  <last_update_submitted_qc>January 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ricardo Augusto Monteiro de Barros Almeida</name_title>
    <organization>Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil</organization>
  </responsible_party>
  <keyword>B-2 microglobulin</keyword>
  <keyword>Serum cytokines</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Resistance</keyword>
  <keyword>HAART</keyword>
  <keyword>Therapeutic failure</keyword>
  <keyword>Genotyping.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

